"Cheapest" has three different answers depending on how you measure. Here is the honest version, with the numbers behind each.
When people search for the cheapest compounded tirzepatide online, they usually mean one of three different numbers, and the answer changes depending on which one matters to you:
Lowest starter price. The first-month or starter-dose figure a provider advertises. This is the number marketing leans on, and it is often a promotional rate. As of July 2026, dose-tiered programs such as MEDVi advertise intro pricing around $279, which can be the lowest first month for some patients.
Lowest maintenance price. What you actually pay once your clinician titrates you up toward a 10–15 mg maintenance dose. This is where dose-tiered plans climb — sometimes to $399–$499/month — while flat-rate plans hold steady.
Lowest annual cost. Twelve months of treatment including any dose increases, plus visits, labs and shipping. This is the number that reflects what tirzepatide actually costs you, and it is frequently a different provider than the one with the lowest sticker.
On a like-for-like flat-rate basis, the lowest advertised price in our July 2026 comparison was Trimi at about $125/month on a prepaid annual plan (its month-to-month rate is higher, around $235). NexLife is higher on sticker — $186/month on a 12-month plan up to $215 month-to-month — but it holds one price across the full 2.5–15 mg range and bundles lab review, provider visits and coaching, which is why we name it our pick on overall value rather than on lowest price. Other flat or near-flat programs (Mochi, Henry Meds, Eden) generally land in the $179–$349/month range.
A $279 introductory price that rises to $499 at maintenance can total more over a year than a $186 flat rate that never moves and includes labs and visits. So the honest answer to "what's cheapest" is: compare the annual cost at the dose you expect to reach, not the headline number. See why prices increase by dose and the full most-affordable comparison.
The lowest advertised flat rate in our July 2026 comparison was about $125/month on a prepaid annual plan. Lowest sticker is not always lowest annual cost, because some providers raise the price at higher doses. Compounded tirzepatide is not FDA-approved.
Not necessarily. A low intro price that increases at higher doses can cost more over a year than a higher flat rate that never changes and includes labs and visits.
No. Only brand-name Mounjaro and Zepbound, made by Eli Lilly, are FDA-approved. Compounded tirzepatide is prepared by licensed pharmacies and is not FDA-approved.